董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Malte Peters | 男 | President, Chief Executive Officer and Director | 63 | 115.14万 | 29.08 | 2026-01-08 |
| Lesley Ann Calhoun | 女 | Director | 60 | 17.63万 | 23.31 | 2026-01-08 |
| Mace Rothenberg | 男 | Director | 69 | 16.97万 | 23.81 | 2026-01-08 |
| Kanishka Pothula | 男 | Director | 41 | 未披露 | 未持股 | 2026-01-08 |
| John Ketchum | 男 | Director | 70 | 19.61万 | 12.89 | 2026-01-08 |
| Sung H. Lee | -- | Independent Director | -- | 未披露 | 0.67 | 2026-01-08 |
| Alexis Borisy | 男 | Director and Chairman of the Board | 54 | 19.20万 | 28.46 | 2026-01-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Malte Peters | 男 | President, Chief Executive Officer and Director | 63 | 115.14万 | 29.08 | 2026-01-08 |
| Adam Crystal | 男 | President of Research and Development | 49 | 172.11万 | 80.77 | 2026-01-08 |
| Daniella Beckman | 女 | Chief Financial Officer | 47 | 115.58万 | 140.58 | 2026-01-08 |
董事简历
中英对照 | 中文 | 英文- Malte Peters
-
Malte Peters于2017年3月加入MorphoSys。任职MorphoSys公司之前，Peters博士曾担任Sandoz International公司的生物制药业务单元的临床开发全球主管。担任该职位之前，他曾担任Novartis肿瘤转化医学系Basel and East Hanover的临床主管和站点主管。Peters博士在德国美因茨大学（University of Mainz，Germany）担任内科和生物化学的教学任命。Peters博士还曾担任加拿大多伦多安进研究所（Amgen Research Institute）的研究科学家，默克集团（Merck KGaA）的癌症研究总监以及Micromet AG的医学总监。Peters博士在德国柏林自由大学（Freie Universit&228；T Berlin）获得医学博士学位，并在意大利帕多瓦大学（University of Padova）以及德国波鸿大学（Bochum）和柏林大学（Berlin）接受培训。在不同的大学从事科学工作后，他在德国美因茨大学获得内科资格。
Malte Peters joined MorphoSys in March 2017. Prior to his time at MorphoSys, Dr. Peters served as the Global Head of Clinical Development of the Biopharmaceuticals Business Unit at Sandoz International. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the Department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany. Dr. Peters also served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KGaA and as Medical Director at Micromet AG. Dr. Peters received his Doctor of Medicine from the Freie Universitat Berlin, Germany, and was trained at the Universities of Padova, Italy, and Bochum and Berlin, Germany. After scientific work at different universities he habilitated in Internal Medicine at the University of Mainz, Germany. - Malte Peters于2017年3月加入MorphoSys。任职MorphoSys公司之前，Peters博士曾担任Sandoz International公司的生物制药业务单元的临床开发全球主管。担任该职位之前，他曾担任Novartis肿瘤转化医学系Basel and East Hanover的临床主管和站点主管。Peters博士在德国美因茨大学（University of Mainz，Germany）担任内科和生物化学的教学任命。Peters博士还曾担任加拿大多伦多安进研究所（Amgen Research Institute）的研究科学家，默克集团（Merck KGaA）的癌症研究总监以及Micromet AG的医学总监。Peters博士在德国柏林自由大学（Freie Universit&228；T Berlin）获得医学博士学位，并在意大利帕多瓦大学（University of Padova）以及德国波鸿大学（Bochum）和柏林大学（Berlin）接受培训。在不同的大学从事科学工作后，他在德国美因茨大学获得内科资格。
- Malte Peters joined MorphoSys in March 2017. Prior to his time at MorphoSys, Dr. Peters served as the Global Head of Clinical Development of the Biopharmaceuticals Business Unit at Sandoz International. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the Department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany. Dr. Peters also served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KGaA and as Medical Director at Micromet AG. Dr. Peters received his Doctor of Medicine from the Freie Universitat Berlin, Germany, and was trained at the Universities of Padova, Italy, and Bochum and Berlin, Germany. After scientific work at different universities he habilitated in Internal Medicine at the University of Mainz, Germany.
- Lesley Ann Calhoun
-
Lesley Ann Calhoun自2020年6月起担任我们首席财务官的执行Vice President。2016年8月至2020年6月，卡尔霍恩女士曾在药物发现，开发和商业阶段的生物制药公司全球血液疗法公司担任多个职位，包括最近担任高级副总裁，财务与管理和首席会计官。在担任这些职务之前，Calhoun女士于2013年1月至2015年9月担任商业阶段生物制药公司HyperionTherapeutics，Inc.的财务Vice President，在该公司于2015年5月被制药公司Horizon Pharma plc收购后继续担任该职务。2005年8月至2013年1月，卡尔霍恩女士还曾担任生物制药公司Innoviva，Inc.（前身为Theravance，Inc.）的高级财务总监兼公司财务总监。在她职业生涯的早期，Calhoun女士从1989年到2001年是Deloitte&Touche LLP审计实践的成员。Calhoun女士在旧金山州立大学商学院（San Francisco State University，College of Business）获得工商管理学士学位，并专注于会计，是一名注册会计师（不活跃）。
Lesley Ann Calhoun has served as Executive Vice President, Chief Financial Officer since June 2020. From August 2016 to June 2020 Ms. Calhoun served in various roles at Global Blood Therapeutics, Inc., a drug discovery, development and commercial-stage biopharmaceutical company, including most recently as Senior Vice President, Finance & Administration and Chief Accounting Officer. Prior to these roles, Ms. Calhoun served as Vice President of Finance at Hyperion Therapeutics, Inc., a commercial stage biopharmaceutical company, from January 2013 to September 2015 continuing in her role after it was acquired by Horizon Pharma plc, a pharmaceutical company, in May 2015. Ms. Calhoun also previously served as Senior Director of Finance, Corporate Controller at Innoviva, Inc. formerly Theravance, Inc., a biopharmaceutical company, from August 2005 to January 2013. Earlier in her career, Ms. Calhoun was a member of the audit practice of Deloitte & Touche LLP from 1989 to 2001. Ms. Calhoun received her B.S. in Business Administration with a concentration in Accounting from San Francisco State University, College of Business and is a Certified Public Accountant (inactive). - Lesley Ann Calhoun自2020年6月起担任我们首席财务官的执行Vice President。2016年8月至2020年6月，卡尔霍恩女士曾在药物发现，开发和商业阶段的生物制药公司全球血液疗法公司担任多个职位，包括最近担任高级副总裁，财务与管理和首席会计官。在担任这些职务之前，Calhoun女士于2013年1月至2015年9月担任商业阶段生物制药公司HyperionTherapeutics，Inc.的财务Vice President，在该公司于2015年5月被制药公司Horizon Pharma plc收购后继续担任该职务。2005年8月至2013年1月，卡尔霍恩女士还曾担任生物制药公司Innoviva，Inc.（前身为Theravance，Inc.）的高级财务总监兼公司财务总监。在她职业生涯的早期，Calhoun女士从1989年到2001年是Deloitte&Touche LLP审计实践的成员。Calhoun女士在旧金山州立大学商学院（San Francisco State University，College of Business）获得工商管理学士学位，并专注于会计，是一名注册会计师（不活跃）。
- Lesley Ann Calhoun has served as Executive Vice President, Chief Financial Officer since June 2020. From August 2016 to June 2020 Ms. Calhoun served in various roles at Global Blood Therapeutics, Inc., a drug discovery, development and commercial-stage biopharmaceutical company, including most recently as Senior Vice President, Finance & Administration and Chief Accounting Officer. Prior to these roles, Ms. Calhoun served as Vice President of Finance at Hyperion Therapeutics, Inc., a commercial stage biopharmaceutical company, from January 2013 to September 2015 continuing in her role after it was acquired by Horizon Pharma plc, a pharmaceutical company, in May 2015. Ms. Calhoun also previously served as Senior Director of Finance, Corporate Controller at Innoviva, Inc. formerly Theravance, Inc., a biopharmaceutical company, from August 2005 to January 2013. Earlier in her career, Ms. Calhoun was a member of the audit practice of Deloitte & Touche LLP from 1989 to 2001. Ms. Calhoun received her B.S. in Business Administration with a concentration in Accounting from San Francisco State University, College of Business and is a Certified Public Accountant (inactive).
- Mace Rothenberg
-
梅斯·罗森伯格担任医学和生物医学发现博物馆主席兼执行董事，自2022年9月起担任该职位。Rothenberg博士此前任职于制药公司辉瑞，公司，曾于2019年至2021年担任首席医疗官兼全球医疗与安全主管，2016年至2018年担任肿瘤学首席开发官，2008年至2016年担任辉瑞肿瘤学临床开发和医疗事务高级副总裁。在加入辉瑞之前，罗森伯格博士在学术界工作了25年，曾任职于得克萨斯大学健康科学中心——圣安东尼奥和范德比尔特大学医学中心的院系。Rothenberg博士是美国内科医师学会和美国临床肿瘤学会的研究员，并在内科和内科肿瘤学方面获得董事会认证。Rothenberg博士自2021年5月以来一直是发现和开发用于选择性调节WNT通路的候选药物的生物技术公司Surrozen, Inc.（NASDAQ：SRZN）的董事会成员，自2021年3月以来一直是私营免疫肿瘤学公司Aulos Bioscience的董事会成员，自2023年1月以来一直是私营生物技术公司Chiara Biosciences的董事会成员。Rothenberg博士获得了宾夕法尼亚大学的学士学位和纽约大学医学院的医学博士学位。他在范德比尔特大学完成了内科住院医师实习，并在美国国家癌症研究所完成了内科肿瘤学研究金。
Mace Rothenberg,serves as the President and Executive Director of the Museum of Medicine and Biomedical Discovery, a position he has held since September 2022. Dr. Rothenberg was previously at Pfizer, Inc., a pharmaceutical company, where he served as Chief Medical Officer and Head of Worldwide Medical and Safety from 2019 to 2021, Chief Development Officer for Oncology from 2016 to 2018, and Senior Vice President for Clinical Development and Medical Affairs for Pfizer Oncology from 2008 to 2016. Prior to joining Pfizer, Dr. Rothenberg spent 25 years in academia, serving on the faculties of the University of Texas Health Science Center — San Antonio and Vanderbilt University Medical Center. Dr. Rothenberg is a fellow of the American College of Physicians and the American Society of Clinical Oncology and is board-certified in Internal Medicine and Medical Oncology. Dr. Rothenberg has been a member of the board of directors of Surrozen, Inc. (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, since May 2021, Aulos Bioscience, a privately-held immuno-oncology company, since March 2021, and Chiara Biosciences, a privately-held biotechnology company, since January 2023. Dr. Rothenberg received his B.A. from the University of Pennsylvania and his M.D. from the New York University School of Medicine. He completed his residency in Internal Medicine at Vanderbilt University and his fellowship in Medical Oncology at the National Cancer Institute. - 梅斯·罗森伯格担任医学和生物医学发现博物馆主席兼执行董事，自2022年9月起担任该职位。Rothenberg博士此前任职于制药公司辉瑞，公司，曾于2019年至2021年担任首席医疗官兼全球医疗与安全主管，2016年至2018年担任肿瘤学首席开发官，2008年至2016年担任辉瑞肿瘤学临床开发和医疗事务高级副总裁。在加入辉瑞之前，罗森伯格博士在学术界工作了25年，曾任职于得克萨斯大学健康科学中心——圣安东尼奥和范德比尔特大学医学中心的院系。Rothenberg博士是美国内科医师学会和美国临床肿瘤学会的研究员，并在内科和内科肿瘤学方面获得董事会认证。Rothenberg博士自2021年5月以来一直是发现和开发用于选择性调节WNT通路的候选药物的生物技术公司Surrozen, Inc.（NASDAQ：SRZN）的董事会成员，自2021年3月以来一直是私营免疫肿瘤学公司Aulos Bioscience的董事会成员，自2023年1月以来一直是私营生物技术公司Chiara Biosciences的董事会成员。Rothenberg博士获得了宾夕法尼亚大学的学士学位和纽约大学医学院的医学博士学位。他在范德比尔特大学完成了内科住院医师实习，并在美国国家癌症研究所完成了内科肿瘤学研究金。
- Mace Rothenberg,serves as the President and Executive Director of the Museum of Medicine and Biomedical Discovery, a position he has held since September 2022. Dr. Rothenberg was previously at Pfizer, Inc., a pharmaceutical company, where he served as Chief Medical Officer and Head of Worldwide Medical and Safety from 2019 to 2021, Chief Development Officer for Oncology from 2016 to 2018, and Senior Vice President for Clinical Development and Medical Affairs for Pfizer Oncology from 2008 to 2016. Prior to joining Pfizer, Dr. Rothenberg spent 25 years in academia, serving on the faculties of the University of Texas Health Science Center — San Antonio and Vanderbilt University Medical Center. Dr. Rothenberg is a fellow of the American College of Physicians and the American Society of Clinical Oncology and is board-certified in Internal Medicine and Medical Oncology. Dr. Rothenberg has been a member of the board of directors of Surrozen, Inc. (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, since May 2021, Aulos Bioscience, a privately-held immuno-oncology company, since March 2021, and Chiara Biosciences, a privately-held biotechnology company, since January 2023. Dr. Rothenberg received his B.A. from the University of Pennsylvania and his M.D. from the New York University School of Medicine. He completed his residency in Internal Medicine at Vanderbilt University and his fellowship in Medical Oncology at the National Cancer Institute.
- Kanishka Pothula
-
Kanishka Pothula，于2023年3月加入Nextech Invest的附属公司Nextech Ventures（US），目前担任管理合伙人。在加入Nextech Ventures（美国）之前，Pothula先生在BVF Partners工作了11年，这是一家专注于生物技术的对冲基金，他在整个任期内担任过各种职务，最近担任的是管理合伙人。Pothula先生拥有乔治敦大学生物技术硕士学位和加州大学圣地亚哥分校生物工程学士学位。
Kanishka Pothula,joined Nextech Ventures (US), an affiliate of Nextech Invest, in March 2023 and currently serves as a Managing Partner. Prior to joining Nextech Ventures (US), Mr. Pothula spent eleven years at BVF Partners, a biotechnology-focused hedge fund, where he served various roles throughout his tenure, most recently as Managing Partner. Mr. Pothula holds a M.S. in biotechnology from Georgetown University and a B.S. in bioengineering from the University of California, San Diego. - Kanishka Pothula，于2023年3月加入Nextech Invest的附属公司Nextech Ventures（US），目前担任管理合伙人。在加入Nextech Ventures（美国）之前，Pothula先生在BVF Partners工作了11年，这是一家专注于生物技术的对冲基金，他在整个任期内担任过各种职务，最近担任的是管理合伙人。Pothula先生拥有乔治敦大学生物技术硕士学位和加州大学圣地亚哥分校生物工程学士学位。
- Kanishka Pothula,joined Nextech Ventures (US), an affiliate of Nextech Invest, in March 2023 and currently serves as a Managing Partner. Prior to joining Nextech Ventures (US), Mr. Pothula spent eleven years at BVF Partners, a biotechnology-focused hedge fund, where he served various roles throughout his tenure, most recently as Managing Partner. Mr. Pothula holds a M.S. in biotechnology from Georgetown University and a B.S. in bioengineering from the University of California, San Diego.
- John Ketchum
-
John Ketchum曾经营Bonnieview Consulting，LLC，这是一家咨询机构，为制药和生物技术公司提供从研发到全面商业化阶段的战略和商业服务。2019年，Ketchum先生创立并继续为CureLeads提供咨询服务，CureLeads是一家为在中东和北非将特种药物商业化的生物医药公司提供一系列服务的公司。1996年至2017年，Ketchum先生在诺华国际集团担任过多个职位，包括2014年至2017年担任新兴增长市场高级副总裁、区域主管，以及2014年至2017年担任拉丁美洲高级副总裁、区域主管。Ketchum先生担任私营肿瘤公司Ernest Pharmaceuticals LLC的顾问和董事会主席。Ketchum先生获得了汉密尔顿学院的学士学位和北卡罗来纳大学教堂山分校的工商管理硕士学位。
John Ketchum,has operated Bonnieview Consulting, LLC, a consulting agency that provides strategic and business services to pharmaceutical and biotech companies from research and development to full commercialization stages. In 2019, Mr. Ketchum founded, and continues to provide advisory services to, CureLeads, a company that provides a range of services for biomedical firms commercializing specialty drugs in the Middle East and North Africa. From 1996 to 2017, Mr. Ketchum held various positions at Novartis International AG, including as Senior Vice President, Region Head, Emerging Growth Markets from 2014 to 2017 and Senior Vice President, Region Head, Latin America, from 2014 to 2017. Mr. Ketchum serves as an advisor and the Chairman of the Board of Ernest Pharmaceuticals LLC, a privately held oncology company. Mr. Ketchum received his B.A. from Hamilton College and his M.B.A. from the University of North Carolina at Chapel Hill. - John Ketchum曾经营Bonnieview Consulting，LLC，这是一家咨询机构，为制药和生物技术公司提供从研发到全面商业化阶段的战略和商业服务。2019年，Ketchum先生创立并继续为CureLeads提供咨询服务，CureLeads是一家为在中东和北非将特种药物商业化的生物医药公司提供一系列服务的公司。1996年至2017年，Ketchum先生在诺华国际集团担任过多个职位，包括2014年至2017年担任新兴增长市场高级副总裁、区域主管，以及2014年至2017年担任拉丁美洲高级副总裁、区域主管。Ketchum先生担任私营肿瘤公司Ernest Pharmaceuticals LLC的顾问和董事会主席。Ketchum先生获得了汉密尔顿学院的学士学位和北卡罗来纳大学教堂山分校的工商管理硕士学位。
- John Ketchum,has operated Bonnieview Consulting, LLC, a consulting agency that provides strategic and business services to pharmaceutical and biotech companies from research and development to full commercialization stages. In 2019, Mr. Ketchum founded, and continues to provide advisory services to, CureLeads, a company that provides a range of services for biomedical firms commercializing specialty drugs in the Middle East and North Africa. From 1996 to 2017, Mr. Ketchum held various positions at Novartis International AG, including as Senior Vice President, Region Head, Emerging Growth Markets from 2014 to 2017 and Senior Vice President, Region Head, Latin America, from 2014 to 2017. Mr. Ketchum serves as an advisor and the Chairman of the Board of Ernest Pharmaceuticals LLC, a privately held oncology company. Mr. Ketchum received his B.A. from Hamilton College and his M.B.A. from the University of North Carolina at Chapel Hill.
- Sung H. Lee
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Alexis Borisy
-
Alexis Borisy ，自2009年起任Dianthus Therapeutics, Inc.的董事会成员，自2011年起担任董事长。他在2009年共同创立 Foundation Medicine，并在2011年5月担任临时首席执行官。他自2009年以来任Third Rock Ventures的合伙人；Third Rock Ventures是一个生命科学风险资本公司，集中在新公司的形成、发展和策略。他在2011年共同创立了一家肿瘤私营公司Blueprint Medicines Corp.，目前担任临时首席执行官和董事会成员。此外，他自2013年7月以来担任 Warp Drive Bio有限责任公司的主席，专注于基因组学；他从2011年到2013年7月担任首席执行官。他从2007年到2012年担任一家生命科学公司FORMA Therapeutics公司的董事长；FORMA Therapeutics专注于针对癌症的治疗。他在2000年创立CombinatoRx公司，现为Zalicus 公司（纳斯达克：ZLCS）；ZLCS是一个药物开发公司；他从2000年到2009年担任其首席执行官和董事会成员。他持有芝加哥大学化学学士学位和哈佛大学文科硕士学位。
Alexis Borisy has served as a member of Parabilis Medicines, Inc.'s board of directors since February 2024. Mr. Borisy is the co founder and operating chairman of Curie.Bio, a new model for venture in biotech. In 2022, Mr. Borisy co founded IDRx, Inc., a biopharmaceutical company. Also in July 2022, Mr. Borisy became a director of Nextech Invest, a Swiss based venture firm, where he also serves as Chairman. Prior to its acquisition by Revolution Medicines, Inc. (NASDAQ: RVMD) in November 2023, Mr. Borisy served as Chief Executive Officer and Chairman of EQRx, Inc., (formerly NASDAQ: EQRX), a biotechnology company, from August 2019 to November 2023. From 2010 to June 2019, Mr. Borisy was a partner at Third Rock Ventures, a series of venture capital funds investing in life science companies. Mr. Borisy co founded Blueprint Medicines Corporation (formerly NASDAQ: BPMC), a biopharmaceutical company, and served as its Interim Chief Executive Officer from 2013 to 2014 and served as a member of its board of directors from 2011 until its acquisition by Sanofi in July 2025. Mr. Borisy co founded Foundation Medicine, Inc. and served as its Interim Chief Executive Officer from 2009 to 2011 and served as a member of its board of directors from 2009 to July 2018, until its acquisition by Roche. In addition, Mr. Borisy serves as a member of the board of directors of Relay Therapeutics, Inc. (NASDAQ: RLAY) and Revolution Medicines, Inc. (NASDAQ: RVMD). During the past five years, Mr. Borisy also served as a member of the board of directors of Magenta Therapeutics, Inc. (formerly NASDAQ: MGTA), Editas Medicine, Inc. (NASDAQ: EDIT), OPKO Health, Inc. (NASDAQ: OPK), and Tango Therapeutics, Inc. (NASDAQ: TNGX). Mr. Borisy received an A.B. in Chemistry from the University of Chicago and an A.M. in Chemistry and Chemical Biology from Harvard University. - Alexis Borisy ，自2009年起任Dianthus Therapeutics, Inc.的董事会成员，自2011年起担任董事长。他在2009年共同创立 Foundation Medicine，并在2011年5月担任临时首席执行官。他自2009年以来任Third Rock Ventures的合伙人；Third Rock Ventures是一个生命科学风险资本公司，集中在新公司的形成、发展和策略。他在2011年共同创立了一家肿瘤私营公司Blueprint Medicines Corp.，目前担任临时首席执行官和董事会成员。此外，他自2013年7月以来担任 Warp Drive Bio有限责任公司的主席，专注于基因组学；他从2011年到2013年7月担任首席执行官。他从2007年到2012年担任一家生命科学公司FORMA Therapeutics公司的董事长；FORMA Therapeutics专注于针对癌症的治疗。他在2000年创立CombinatoRx公司，现为Zalicus 公司（纳斯达克：ZLCS）；ZLCS是一个药物开发公司；他从2000年到2009年担任其首席执行官和董事会成员。他持有芝加哥大学化学学士学位和哈佛大学文科硕士学位。
- Alexis Borisy has served as a member of Parabilis Medicines, Inc.'s board of directors since February 2024. Mr. Borisy is the co founder and operating chairman of Curie.Bio, a new model for venture in biotech. In 2022, Mr. Borisy co founded IDRx, Inc., a biopharmaceutical company. Also in July 2022, Mr. Borisy became a director of Nextech Invest, a Swiss based venture firm, where he also serves as Chairman. Prior to its acquisition by Revolution Medicines, Inc. (NASDAQ: RVMD) in November 2023, Mr. Borisy served as Chief Executive Officer and Chairman of EQRx, Inc., (formerly NASDAQ: EQRX), a biotechnology company, from August 2019 to November 2023. From 2010 to June 2019, Mr. Borisy was a partner at Third Rock Ventures, a series of venture capital funds investing in life science companies. Mr. Borisy co founded Blueprint Medicines Corporation (formerly NASDAQ: BPMC), a biopharmaceutical company, and served as its Interim Chief Executive Officer from 2013 to 2014 and served as a member of its board of directors from 2011 until its acquisition by Sanofi in July 2025. Mr. Borisy co founded Foundation Medicine, Inc. and served as its Interim Chief Executive Officer from 2009 to 2011 and served as a member of its board of directors from 2009 to July 2018, until its acquisition by Roche. In addition, Mr. Borisy serves as a member of the board of directors of Relay Therapeutics, Inc. (NASDAQ: RLAY) and Revolution Medicines, Inc. (NASDAQ: RVMD). During the past five years, Mr. Borisy also served as a member of the board of directors of Magenta Therapeutics, Inc. (formerly NASDAQ: MGTA), Editas Medicine, Inc. (NASDAQ: EDIT), OPKO Health, Inc. (NASDAQ: OPK), and Tango Therapeutics, Inc. (NASDAQ: TNGX). Mr. Borisy received an A.B. in Chemistry from the University of Chicago and an A.M. in Chemistry and Chemical Biology from Harvard University.
高管简历
中英对照 | 中文 | 英文- Malte Peters
Malte Peters于2017年3月加入MorphoSys。任职MorphoSys公司之前，Peters博士曾担任Sandoz International公司的生物制药业务单元的临床开发全球主管。担任该职位之前，他曾担任Novartis肿瘤转化医学系Basel and East Hanover的临床主管和站点主管。Peters博士在德国美因茨大学（University of Mainz，Germany）担任内科和生物化学的教学任命。Peters博士还曾担任加拿大多伦多安进研究所（Amgen Research Institute）的研究科学家，默克集团（Merck KGaA）的癌症研究总监以及Micromet AG的医学总监。Peters博士在德国柏林自由大学（Freie Universit&228；T Berlin）获得医学博士学位，并在意大利帕多瓦大学（University of Padova）以及德国波鸿大学（Bochum）和柏林大学（Berlin）接受培训。在不同的大学从事科学工作后，他在德国美因茨大学获得内科资格。
Malte Peters joined MorphoSys in March 2017. Prior to his time at MorphoSys, Dr. Peters served as the Global Head of Clinical Development of the Biopharmaceuticals Business Unit at Sandoz International. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the Department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany. Dr. Peters also served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KGaA and as Medical Director at Micromet AG. Dr. Peters received his Doctor of Medicine from the Freie Universitat Berlin, Germany, and was trained at the Universities of Padova, Italy, and Bochum and Berlin, Germany. After scientific work at different universities he habilitated in Internal Medicine at the University of Mainz, Germany.- Malte Peters于2017年3月加入MorphoSys。任职MorphoSys公司之前，Peters博士曾担任Sandoz International公司的生物制药业务单元的临床开发全球主管。担任该职位之前，他曾担任Novartis肿瘤转化医学系Basel and East Hanover的临床主管和站点主管。Peters博士在德国美因茨大学（University of Mainz，Germany）担任内科和生物化学的教学任命。Peters博士还曾担任加拿大多伦多安进研究所（Amgen Research Institute）的研究科学家，默克集团（Merck KGaA）的癌症研究总监以及Micromet AG的医学总监。Peters博士在德国柏林自由大学（Freie Universit&228；T Berlin）获得医学博士学位，并在意大利帕多瓦大学（University of Padova）以及德国波鸿大学（Bochum）和柏林大学（Berlin）接受培训。在不同的大学从事科学工作后，他在德国美因茨大学获得内科资格。
- Malte Peters joined MorphoSys in March 2017. Prior to his time at MorphoSys, Dr. Peters served as the Global Head of Clinical Development of the Biopharmaceuticals Business Unit at Sandoz International. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the Department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany. Dr. Peters also served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KGaA and as Medical Director at Micromet AG. Dr. Peters received his Doctor of Medicine from the Freie Universitat Berlin, Germany, and was trained at the Universities of Padova, Italy, and Bochum and Berlin, Germany. After scientific work at different universities he habilitated in Internal Medicine at the University of Mainz, Germany.
- Adam Crystal
Adam Crystal自2019年2月起担任我们的首席医疗官。2014年5月至2019年2月，Crystal博士担任Novartis Institute for Biomedical Research的临床项目负责人和高级总监，在那里他领导了Novartis AG（CDK’；S NYSE:NVS）等分子的早期开发试验，现在批准了CDK4/6抑制剂Ribociclib和选择性雌激素受体降解剂LSZ102。Crystal博士自2013年以来一直担任马萨诸塞州总医院的医学助理，在那里他是肿瘤主治医师，并于2013年至2018年担任哈佛医学院的医学讲师。从2010年到2014年，Crystal博士还是马萨诸塞州总医院（Massachusetts General Hospital）的实验室研究员，他在靶向疗法的耐药机制方面的工作获得了美国临床肿瘤学会征服癌症青年研究员奖的认可，并在《科学》杂志上发表。Crystal博士在麻省总医院（Massachusetts General Hospital）接受内科培训，然后于2013年在麻省总医院癌症中心（Massachusetts General Hospital Cancer Center）和达纳·法伯癌症研究所（Dana Farber Cancer Institute）完成医学肿瘤学研究金培训。Crystal博士拥有宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）神经科学的医学博士学位和博士学位。
Adam Crystal,served as Chief Medical Officer of C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, from February 2019 to February 2023. From May 2014 to February 2019, Dr. Crystal was a Clinical Program Leader, Senior Director, at Novartis Institutes for BioMedical Research. Dr. Crystal has served as a medical oncologist at Massachusetts General Hospital, where he studied resistance mechanisms to targeted therapies. Dr. Crystal trained at Massachusetts General Hospital in internal medicine and then completed fellowship training in medical oncology at the Massachusetts General Hospital Cancer Center and the Dana-Farber Cancer Institute in 2013. Dr. Crystal holds an M.D. and a Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine.- Adam Crystal自2019年2月起担任我们的首席医疗官。2014年5月至2019年2月，Crystal博士担任Novartis Institute for Biomedical Research的临床项目负责人和高级总监，在那里他领导了Novartis AG（CDK’；S NYSE:NVS）等分子的早期开发试验，现在批准了CDK4/6抑制剂Ribociclib和选择性雌激素受体降解剂LSZ102。Crystal博士自2013年以来一直担任马萨诸塞州总医院的医学助理，在那里他是肿瘤主治医师，并于2013年至2018年担任哈佛医学院的医学讲师。从2010年到2014年，Crystal博士还是马萨诸塞州总医院（Massachusetts General Hospital）的实验室研究员，他在靶向疗法的耐药机制方面的工作获得了美国临床肿瘤学会征服癌症青年研究员奖的认可，并在《科学》杂志上发表。Crystal博士在麻省总医院（Massachusetts General Hospital）接受内科培训，然后于2013年在麻省总医院癌症中心（Massachusetts General Hospital Cancer Center）和达纳·法伯癌症研究所（Dana Farber Cancer Institute）完成医学肿瘤学研究金培训。Crystal博士拥有宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）神经科学的医学博士学位和博士学位。
- Adam Crystal,served as Chief Medical Officer of C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, from February 2019 to February 2023. From May 2014 to February 2019, Dr. Crystal was a Clinical Program Leader, Senior Director, at Novartis Institutes for BioMedical Research. Dr. Crystal has served as a medical oncologist at Massachusetts General Hospital, where he studied resistance mechanisms to targeted therapies. Dr. Crystal trained at Massachusetts General Hospital in internal medicine and then completed fellowship training in medical oncology at the Massachusetts General Hospital Cancer Center and the Dana-Farber Cancer Institute in 2013. Dr. Crystal holds an M.D. and a Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine.
- Daniella Beckman
Daniella Beckman，自2012年6月起担任5：01 Acquisition的高级副总裁、首席财务官和财务主管。Bechman女士自2019年9月起担任Tango Therapeutics，Inc.的首席财务官。在加入Tango之前，Beckman女士于2015年11月至2019年9月期间通过Beckman Consulting LLC为早期生物技术公司提供咨询和临时首席财务官服务。Beckman女士是Idenix Pharmaceuticals的首席财务官，直到Idenix Pharmaceuticals于2014年被默沙东收购。Beckman女士担任Translate Bio, Inc.纳斯达克：TBIO和Vor Biopharma，Inc.（纳斯达克：VOR）董事会审计委员会主席。Beckman女士拥有波士顿大学工商管理/会计学学士学位，是马萨诸塞州的注册会计师。
Daniella Beckman has served on 5:01 Acquisition board of directors since the completion of 5:01 Acquisition IPO. Ms. Bechman has served as the chief financial officer of Tango Therapeutics, Inc. since September 2019. Prior to Tango, Ms. Beckman provided consulting and interim chief financial officer services for early- stage biotechnology companies through Beckman Consulting LLC from November 2015 to September 2019. Prior to consulting, Ms. Beckman was the chief financial officer of Idenix Pharmaceuticals until its acquisition by Merck in 2014. Ms. Beckman serves as Chair of Audit Committee for the boards of directors of Translate Bio, Inc. Nasdaq: TBIO and Vor Biopharma, Inc. (Nasdaq: VOR). Ms. Beckman has a B.S. in business administration/accounting from Boston University and is a certified public accountant in Massachusetts.- Daniella Beckman，自2012年6月起担任5：01 Acquisition的高级副总裁、首席财务官和财务主管。Bechman女士自2019年9月起担任Tango Therapeutics，Inc.的首席财务官。在加入Tango之前，Beckman女士于2015年11月至2019年9月期间通过Beckman Consulting LLC为早期生物技术公司提供咨询和临时首席财务官服务。Beckman女士是Idenix Pharmaceuticals的首席财务官，直到Idenix Pharmaceuticals于2014年被默沙东收购。Beckman女士担任Translate Bio, Inc.纳斯达克：TBIO和Vor Biopharma，Inc.（纳斯达克：VOR）董事会审计委员会主席。Beckman女士拥有波士顿大学工商管理/会计学学士学位，是马萨诸塞州的注册会计师。
- Daniella Beckman has served on 5:01 Acquisition board of directors since the completion of 5:01 Acquisition IPO. Ms. Bechman has served as the chief financial officer of Tango Therapeutics, Inc. since September 2019. Prior to Tango, Ms. Beckman provided consulting and interim chief financial officer services for early- stage biotechnology companies through Beckman Consulting LLC from November 2015 to September 2019. Prior to consulting, Ms. Beckman was the chief financial officer of Idenix Pharmaceuticals until its acquisition by Merck in 2014. Ms. Beckman serves as Chair of Audit Committee for the boards of directors of Translate Bio, Inc. Nasdaq: TBIO and Vor Biopharma, Inc. (Nasdaq: VOR). Ms. Beckman has a B.S. in business administration/accounting from Boston University and is a certified public accountant in Massachusetts.